Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

Haemophilia

Volumn 16, Issue 1, 2010, Pages 90-100

  Ettingshausen, C ^a   Kreuz, W ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Arthropathy; Blood coagulation factor inhibitors; FEIBA; Haemorrhage; Immune tolerance induction; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; THROMBIN;

ARTHROPATHY; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FOLLOW UP; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INDIVIDUALIZATION; INFANT; MALE; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; MUSCLE BLEEDING; PATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RISK REDUCTION; SCORING SYSTEM; THROMBIN TIME; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

BLOOD COAGULATION; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; INFANT; JOINTS; PROSPECTIVE STUDIES; THROMBIN;

EID: 73949129681     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02116.x     Document Type: Article

References (47)

1. Soucie JM, Cianfrini C, Janco RL. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004, 103:2467-73.
2. Leissinger CA. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 2006, 12(Suppl. 6):67-72.
3. Morfini M, Haya S, Tagariello G. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007, 13:606-12.
4. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006, 12(Suppl. 6):74-9.
5. Escuriola-Ettingshausen C, Kreuz W, Auerswald G, Brackmann HH. The role of VWF in immune tolerance induction - the German experience. Haemophilia 2004, 10(Suppl. 3):54.
6. Escuriola Ettingshausen C, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005, 16(Suppl. 1):S27-31.
7. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-63.
8. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?-The German experience. Haemophilia 1998, 4:413-7.
9. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999, 105:1109-13.
10. Fischer K, van der Bom JG, Mauser-Bunschoten EP. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002, 99:2337-41.
11. Berntorp E, Astermark J, Björkman S. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003, 9(Suppl. 1):1-4.
12. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
13. Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 2006, 12(Suppl. 5):4-13.
14. Gomperts ED. FEIBA safety and tolerability profile. Haemophilia 2006, 12(Suppl. 5):14-9.
15. Kreuz W, Escuriola-Ettingshausen C, Martinez I, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (Feiba) for long-term prophylaxis in patients with high-responding inhibitors. Blood 2000, 96:1140.
16. Escuriola-Ettingshausen C, Martinez Saguer I, Funk MB. Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors. J Thromb Haemost 2003, 1(Suppl):P1628.
17. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003, 9:261-8.
18. Valentino L. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 2006, 12(Suppl. 5):26-31.
19. Ewing N. Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with factor eight inhibitor bypassing activity, vapor heated (FEIBA VH). J Thromb Haemost 2005, 3(Suppl. 1):P2036.
20. Saxena K, Hawk S, Stevens B, Sexauer C. Long-term clinical experience with FEIBA VH in hemophilia patients with inhibitors. J Thromb Haemost 2005, 3(Suppl. 1):P0838.
21. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia 2005, 11:638-41.
22. Cheng S, Chen Y, Chiang J. FEIBA prophylaxis in hemophilia A patient with inhibitors decreases bleeding episodes, improves joint function and enhance quality of life. Haemophilia 2006, 12(Suppl. 2):14 PO 371.
23. Lambert T, Fressinaud E, Goudemand J, Rafowicz A. Can long-term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitor? Haemophilia 2006, 12(Suppl. 2):14 PO 399.
24. Schino M, Mancuso G, Morfini M, Piseddu G, Sbrighi P. aPCC (FEIBA) home therapy retrospective survey in long-term secondary prophylaxis on hemophilia A patients with factor VIII inhibitor. Haemophilia 2006, 12(Suppl. 2):14 PO 424.
25. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007, 13:249-55.
26. Ohga S, Nomura A, Takada H, Suga N, Hara T. Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor. Am J Hematol 2007, 82:145-9.
27. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12:352-62.
28. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years''Bonn protocol'. Vox Sang 1996, 70:30-5.
29. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980, 149:153-9.
30. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993, 30:3-6.
31. Váradi K, Négrier C, Berntorp E. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003, 1:2374-80.
32. Váradi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004, 10(Suppl. 2):17-21.
33. Astermark J, Rocino A, Von Depka M. Current use of bypassing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007, 13:38-45.
34. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992, 232:25-32.
35. van den Berg HM, Fischer K, Mauser-Bunschoten EP. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001, 112:561-5.
36. Panicker J, Warrier I, Lusher J. The impact of prophylaxis on children with severe haemophilia. Haemophilia 2002, 8:489-90.
37. Yee TT, Beeton K, Griffioen A. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002, 8:76-82.
38. Fischer K, Van Der Bom JG, Prejs R. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001, 7:544-50.
39. Jiménez-Yuste V, Alvarez MT, Martín-Salces M. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009, 15:203-9.
40. Ewenstein B, Giangrande PL, Morfini M, Tjønnfjord GE, Kraut E, Luu H. Evaluation of FEIBA for prophylaxis in patients with inhibitors. Haemophilia 2004, 10(Suppl. 3):114.
41. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA®: mode of action. Haemophilia 2004, 10(Suppl. 2):3-9.
42. Hemker HC, Giesen P, Al DieriR. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4-15.
43. Turecek PL, Váradi K, Keil B. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003, 33:16-22.
44. Dargaud Y, Béguin S, Lienhart A. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005, 93:475-80.
45. Luu H, Ewenstein B. FEIBA® safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004, 10(Suppl. 2):10-6.
46. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008, 14:39-43.
47. Ewing NP, Pullens L, De Guzman C. Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis. J Thromb Haemost 2007, 5(Suppl. 2):P-T-158.